logo
Alphawave Talks Boost Qualcomm Stock Ahead

Alphawave Talks Boost Qualcomm Stock Ahead

Yahoo5 days ago

Qualcomm's (NASDAQ:QCOM) stock got an early boost todayup just over 2% before markets openedafter it snagged a fresh deadline to firm up its roughly $1.4 billion bid for U.K. chip IP specialist Alphawave.
Earlier, QCOM had dipped about 1.35% during normal hours, but word that Alphawave's put up or shut up clock has been reset to June 2 (the third push-out since late April) lit a spark under shares. Alphawave's valuation clocks in at about 1.1 billionaround $1.4 billionand its own stock jumped 8% on the news, even though no official offer has landed yet.
Warning! GuruFocus has detected 5 Warning Signs with QCOM.
Why it matters: Alphawave's tech is a linchpin for AI processor connections, which lines up perfectly with Qualcomm's big-picture AI roadmap. As J.P. Morgan's Samik Chatterjee points out, snapping up Alphawave would slot neatly alongside QCOM's Nuvia buy, beefing up its data-center connectivity chops and turbocharging its CPU and AI inference play.
For investors, the potential payoff is clearseal this deal, and Qualcomm could speed up its push into next-gen data centers and AI hardware, opening fresh revenue channels just as demand for high-speed, low-latency chips ramps up.
Now all eyes are on June 2: will Qualcomm finally make a formal bid, or will Alphawave buy more time? Either way, today's extension keeps the takeover dramaand the stock's momentumright on track.
The chart above shows Qualcomm Inc. (NASDAQ:QCOM) with a 12-month average price target of $177.64 as of May 27, 2025, representing a projected upside of 22.19% from its current level.
The highest analyst target stands at $270, suggesting strong bullish sentiment, while the lowest forecast is $140, indicating downside risk. The intrinsic or GF Value is pegged at $160.10, hinting that the stock may be slightly undervalued based on current fundamentals. Overall, analysts anticipate moderate growth, with a wide range reflecting varied views on the chipmaker's prospects.
This article first appeared on GuruFocus.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China Liberal Education announces suspension of Nasdaq trading
China Liberal Education announces suspension of Nasdaq trading

Business Insider

time3 hours ago

  • Business Insider

China Liberal Education announces suspension of Nasdaq trading

China Liberal Education (CLEU) announced that on May 30, 2025, the Company received notice from The Nasdaq Stock Market LLC that the Company's securities will be suspended from trading on Nasdaq effective June 3, 2025. The suspension is due to the Company's failure to submit a request for an extended stay or otherwise address the delinquency in filing its annual report on Form 20-F for the fiscal year ended December 31, 2024, in its written submissions to the Nasdaq Hearings Panel. Confident Investing Starts Here:

Jim Cramer and Wall Street Are Watching DraftKings Inc. (DKNG)
Jim Cramer and Wall Street Are Watching DraftKings Inc. (DKNG)

Yahoo

time3 hours ago

  • Yahoo

Jim Cramer and Wall Street Are Watching DraftKings Inc. (DKNG)

We recently published a list of . In this article, we are going to take a look at where DraftKings Inc. (NASDAQ:DKNG) stands against other stocks on Jim Cramer and Wall Street's radar. During the May 2 episode, Cramer mentioned DraftKings Inc. (NASDAQ:DKNG) and said: 'Will DraftKings make a comeback here? We like this company very much, but the stock does seem stalled, doesn't it? Maybe it needs more states to legalize sports betting.' A woman at a betting table paying out customers who won their sports bets. DraftKings Inc. (NASDAQ:DKNG) is a digital gaming company that focuses on online sports betting, daily fantasy sports, online casino games, and a digital collectibles marketplace. Additionally, the company develops software for sports betting and iGaming across both online and retail platforms. On May 30, Morgan Stanley analyst Stephen Grambling reduced the price target on DraftKings (NASDAQ:DKNG) from 53 to $51 while maintaining an Overweight rating. The firm slightly increased estimates for its Gaming & Lodging coverage due to stronger first-quarter results, expected guidance, and updated valuations based on higher multiples. The analyst noted that low valuations in the sector indicate the market remains cautious in the near term. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

Yahoo

time5 hours ago

  • Yahoo

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US." Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. About ASP Isotopes Inc. ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company has isotope enrichment facilities in Pretoria, South Africa. For more information, please visit About Isotopia Molecular Imaging Ltd. Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy. This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. Contact: eshalom@ SOURCE Isotopia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store